Longeveron
Life-sciences company developing biological solutions for aging and aging-associated diseases.
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (77 %) | (6 %) | (42 %) | 237 % | (28 %) | 51 % | 1402 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (1258 %) | (1427 %) | (2828 %) | (651 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1305 %) | (1541 %) | (3020 %) | (668 %) | (1331 %) | (1184 %) | (21 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 543 % | 767 % | 1279 % | 340 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Longeveron is a biotechnology company specializing in regenerative medicine aimed at improving healthspan and treating aging-related conditions. The company focuses on developing therapies for Aging Frailty, neurodegenerative diseases, Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Longeveron's lead investigational product is derived from culture-expanded medicinal signaling cells (MSCs) sourced from the bone marrow of young, healthy adult donors. These cells are used in clinical trials to assess their efficacy in treating various conditions. The company operates primarily in the healthcare and biotechnology markets, targeting patients suffering from age-related and degenerative diseases. Longeveron generates revenue through the development and potential commercialization of its cell-based therapies. The business model includes conducting clinical trials, securing regulatory approvals, and partnering with healthcare providers for distribution and treatment implementation.
Keywords: regenerative medicine, aging frailty, neurodegenerative diseases, clinical trials, MSCs, biotechnology, healthspan, cell-based therapies, healthcare, biotechnology market.